NCT03553004进行中（未招募）2 期
Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 18
- 试验地点
- 6
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Screening tumor tissue analysis positive with germline or somatic mutation in genes involved in DNA repair.
- •Ability of participant or Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent.
- •Able to swallow oral study drug
- •Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas
- •Measurable disease
- •Patients with history of other, non-pancreatic cancers with no evidence of active disease are eligible.
- •Participants who have had any prior chemotherapy as first line and/or second line therapy for metastatic disease are eligible to seek enrollment. Patients who refuse chemotherapy or do not tolerate chemotherapy are eligible.
- •Patients must have adequate organ function
- •Women must have a negative serum pregnancy test within 72 hours to taking study treatment.
- •Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use approved forms of contraception prior to study entry, for the duration of study participation, and for 180 days following completion of therapy.
排除标准
- •Patients simultaneously enrolled in any therapeutic clinical trial
- •Patients have had investigational therapy administered within the past 4 weeks
- •Current or anticipated use of other investigational agents while participating in this study.
- •Patient has had prior treatment with a known poly polymerase inhibitor
- •Psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant, breast feeding or expecting to conceive children while receiving study treatment and for 180 days after the last dose of study treatment. There is a potential for congenital abnormalities and for this regimen to harm breast feeding infants.
- •Patients must not have a known hypersensitivity to the components of niraparib or the excipients
- •Patients must not have had major surgery within the last 3 weeks of starting the study and patient must have recovered from any effects of any major surgery
- •Patients must not have had radiotherapy encompassing more than 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to Day 1 of protocol therapy
- •Patients must not be immuno-compromised. Patients with splenectomy are allowed.
- •Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment
- •Patients must not have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate
- •Patients must not have known, symptomatic brain or leptomeningeal metastases
- •Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
研究组 & 干预措施
Niraparib Treatment
Experimental
- Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)
- (Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL)).
干预措施: Niraparib Treatment (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: 8 weeks
Defined as the percentage of participants with overall response to therapy at 8 weeks, defined as Partial Response or Complete Response (PR + CR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
次要结局
- Overall Survival (OS)(Up to 5 years)
- Disease Control(8 weeks)
- Progression Free Survival (PFS)(Up to 5 years)
- Duration of Response(Up to 5 years)
- Proportion of participants with adverse events (AEs)(Up to 5 years)
研究者
研究点 (6)
Loading locations...
相似试验
尚未招募
2 期
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersMetastatic Breast Cancer in Germline-PALB2 Mutations CarriersNCT05232006Assistance Publique - Hôpitaux de Paris12
进行中（未招募）
2 期
Niraparib in Tumors Metastatic to the CNSMetastatic CancerCentral Nervous System CancerNCT04992013Massachusetts General Hospital20
招募中
2 期
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)Brain MetastasesNCT05700721M.D. Anderson Cancer Center120
Unknown
2 期
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic CancerStage IV Pancreatic CancerNCT04377048National Taiwan University Hospital38
招募中
2 期
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaNCT06576115Barbara Ann Karmanos Cancer Institute30